48 results on '"Jeziskova, Ivana"'
Search Results
2. Effective NPM1 plasmid standards selection for minimal/measurable residual disease monitoring in acute myeloid leukemia
3. Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data.
4. De novo accelerated phase of chronic myeloid leukemia should be recognized even in the era of tyrosine kinase inhibitors
5. P669: ANALYSIS OF FACTORS INFLUENCING THE DECISION TO STOP TKI TREATMENT IN CML PATIENTS IN DEEP MOLECULAR RESPONSE
6. The influence of mutational status and biological characteristics of acute myeloid leukemia on xenotransplantation outcomes in NOD SCID gamma mice
7. Donor-derived DNA variability in fingernails of acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation detected by direct PCR
8. Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients
9. Somatic Mutations in Myeloid Transcription Factors and in Activated Signaling Pathway, but Not in Epigenetic Modifier Pathway, Predict the Risk of Treatment Failure and Progression to Advanced Phase in Chronic Myeloid Leukemia
10. Distribution of mutations in DNMT3A gene and the suitability of mutations in R882 codon for MRD monitoring in patients with AML
11. Palbociclib and Ponatinib Suppress Acute Myeloid Leukemia in Patient-Derived Xenograft
12. Role of Treatment in the Appearance and Selection of BCR-ABL1 Kinase Domain Mutations
13. Analysis of Mutations in the BCR-ABL1 Kinase Domain, Using Direct Sequencing: Detection of the T315I Mutation in Bone Marrow CD34+ Cells of a Patient with Chronic Myelogenous Leukemia 6 Months Prior to its Emergence in Peripheral Blood
14. Real World Population- Based Data from Nationwide Registry Support the Existence of Accelerated Phase in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients Even in Tyrosine Kinase Inhibitors (TKIs) Era
15. Final Report: Somatic Mutations and HMGCLL1 Haplotype Are Not Associated with Molecular Relapse-Free Survival in Patients with Chronic Myeloid Leukemia Who Attempt Treatment-Free Remission
16. New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia Patients Evidenced from Mutational Kinetic Analysis Based on Pairwise Comparison
17. BCR-ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next-generation sequencing
18. Evaluation of two CE-IVD tests for BCR-ABL1 transcript monitoring of chronic myeloid leukemia patients
19. Treatment of molecular relapse in patients with acute myeloid leukemia using clofarabine monotherapy
20. Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations
21. Clonal hierarchy of main molecular lesions in acute myeloid leukaemia
22. Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure
23. The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy
24. A Comparison of Two Standardized Quantitative RT-PCRs with CE IVD Kit for Digital PCR in CML Patients with Different Level of BCR-ABL1 Transcripts
25. Prognostic significance of mutation profile at diagnosis and mutation persistence during disease remission in adult acute myeloid leukaemia patients
26. Evaluation of two CE-IVD tests for BCR-ABL1 transcript monitoring of chronic myeloid leukemia patients.
27. Half: A Prospective Multi-Centre Phase II Clinical Trial Evaluating the Efficacy and Safety of Tyrosine Kinase Inhibitors' Discontinuation after Two-Step Dose Reduction in Patients with Chronic Myeloid Leukemia in Deep Molecular Remission
28. Clonal hierarchy of main molecular lesions in acute myeloid leukaemia.
29. Persistence of Mutations during Remission in 114 AML Patients
30. Methscore As a New Prognostic Tool for Complex DNA Methylation Changes Assessment in Patients with Acute Myeloid Leukemia
31. Genesis of new allele at locus D2S1360 in leukemia patient
32. Novel complex mutation in NPM1 gene in patient with acute myeloid leukemia
33. Limited efficacy of HLA-haploidentical peripheral blood stem cell infusion in treatment of elderly patients with acute myelogenous leukaemia
34. BCR-ABL1kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next-generation sequencing
35. Clonal heterogeneity in patients with cytogenetically normal acute myeloid leukemia withNPM1mutations
36. Quantitative detection ofIDH2mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations inNPM1gene
37. Treatment of molecular relapse in patients with acute myeloid leukemia using clofarabine monotherapy
38. IDH2mutations in patients with acute myeloid leukemia: missense p.R140 mutations are linked to disease status
39. Failure of molecular diagnostics in chronic myeloid leukemia: an aberrant form of e13a2BCR–ABLtranscript causing false-negative results by standard polymerase chain reaction
40. Monitoring of Minimal Residual Disease in NPM1 Mutated Acute Myeloid Leukemia (AML) – a Single Center Experience in 27 Patients.
41. Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: Frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression
42. Novel complex mutation in NPM1 gene in patient with acute myeloid leukemia.
43. Clonal heterogeneity in patients with cytogenetically normal acute myeloid leukemia with NPM1 mutations.
44. Quantitative detection of IDH2 mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations in NPM1 gene.
45. Failure of molecular diagnostics in chronic myeloid leukemia: an aberrant form of e13a2 BCR–ABL transcript causing false-negative results by standard polymerase chain reaction.
46. IDH2 mutations in patients with acute myeloid leukemia: missense p.R140 mutations are linked to disease status.
47. Limited efficacy of HLA-haploidentical peripheral blood stem cell infusion in treatment of elderly patients with acute myelogenous leukaemia.
48. Simulation of AML Clonality in Patient-Derived Xenografts
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.